Advent Access has developed an innovative biomedical device that empowers patients with kidney problems to perform hemodialysis independently, safely and more affordably at home or in novel care environments, thereby reducing vascular access related hospitalization costs. The device uses a novel implant technology that reduces the pain of dialysis by improving vascular access reliability. The technology can work with different existing dialysis machines, and is ready for market launch, having received the CE Mark certificate and ISO 13485 Certification.
Prior to founding Advent Access, the CEO has an excellent track record as a researcher and research manager, having been awarded more than 50 patents in renal, cardiovascular and surgical technologies, and recognized by MIT Tech Review as one of the “Top 10 Innovators under 35, Asia Pacific” in 2014. He has also acquired valuable business management experience as Program Director of Singapore-Stanford Biodesign (SSB), a joint venture between the Singapore government and Stanford University that has expanded to several Asian countries under his leadership.
As Japan is the world’s second largest kidney treatment market, Advent Access is keen to explore potential investment by Japanese VCs, partnership with leading Japanese biomedical companies, and collaboration with leading Japanese nephrologists and vascular access surgeons.